One of the means being explored is a laboratory formulary. If the utility of a certain test is questionable, then it might not be available to all ordering physicians. This not only helps to cut lab tests, but very often relieves some of the financial burden on patients.
Some of the “solutions” that the company offers are 20 years old. Still its emphasis on consumer guidance ensures that the right treatment is given to the right patient at the right time, says Helen Darling, former head of the National Business Group on Health.
Mark. W. Friedberg, MD, one of the foremost experts on the patient-centered medical home explains why the high-profile failures of some recent demonstration projects shouldn’t mean the end for this care delivery system. The challenges can be overcome with some different approaches.
They are: value-based insurance design, which has achieved benefits more generous than average; intervention by community-based pharmacists, which improved adherence; and pharmacist intervention in a patient-centered medical home model, which delivered results encouraging enough to extend the program to specialty medications.
Stanford University researchers argue in a JAMA piece that as many as one third of published randomized clinical trials could be reanalyzed to modify the conclusions of how many and what types of patients need to be treated.
Anonymized patient-level longitudinal data (APLD), which has its roots in claims used by payers, constitutes a common resource for facilitating dialogue between pharmaceutical companies and health plans.
Health plans cheered along with other players in the managed care industry when the Leapfrog Group recently announced that there has been a dramatic decline in early elective deliveries of babies. “The national average of 4.6% in 2013 stands in sharp contrast to the national average of 17% in 2010,”…